share_log

Virpax Pharmaceuticals | S-1/A: General form for registration of securities under the Securities Act of 1933 (Amendment)

Virpax Pharmaceuticals | S-1/A: General form for registration of securities under the Securities Act of 1933 (Amendment)

Virpax制药 | S-1/A：证券上市注册声明(修正)
美股SEC公告 ·  05/13 17:34

Moomoo AI 已提取核心信息

Virpax Pharmaceuticals, Inc. (Virpax), a preclinical-stage pharmaceutical company, has announced an offering of up to 2,008,032 shares of common stock, alongside Series A-1 and Series A-2 Common Warrants to purchase an equivalent number of shares. Additionally, the offering includes up to 2,008,032 Pre-Funded Warrants to purchase shares of common stock. The Pre-Funded Warrants are immediately exercisable at a nominal exercise price and are being offered to certain investors whose purchase would result in ownership exceeding 4.99% or 9.99% of outstanding common stock post-transaction. The offering is conducted on a best-efforts basis by A.G.P./Alliance Global Partners as the sole Placement Agent. The company plans to use the net proceeds for working capital, general corporate purposes, and to potentially pay a portion of the $2.5 million due on July 1, 2024, as part of a Settlement Agreement with Sorrento Therapeutics, Inc. and Scilex Pharmaceuticals Inc. The offering is expected to close within two business days from the commencement date.
Virpax Pharmaceuticals, Inc. (Virpax), a preclinical-stage pharmaceutical company, has announced an offering of up to 2,008,032 shares of common stock, alongside Series A-1 and Series A-2 Common Warrants to purchase an equivalent number of shares. Additionally, the offering includes up to 2,008,032 Pre-Funded Warrants to purchase shares of common stock. The Pre-Funded Warrants are immediately exercisable at a nominal exercise price and are being offered to certain investors whose purchase would result in ownership exceeding 4.99% or 9.99% of outstanding common stock post-transaction. The offering is conducted on a best-efforts basis by A.G.P./Alliance Global Partners as the sole Placement Agent. The company plans to use the net proceeds for working capital, general corporate purposes, and to potentially pay a portion of the $2.5 million due on July 1, 2024, as part of a Settlement Agreement with Sorrento Therapeutics, Inc. and Scilex Pharmaceuticals Inc. The offering is expected to close within two business days from the commencement date.
处于临床前阶段的制药公司Virpax Pharmicals, Inc.（Virpax）宣布发行多达2,008,032股普通股，以及购买等量股票的A-1和A-2系列普通认股权证。此外，此次发行还包括多达2,008,032份用于购买普通股的预先注资认股权证。预筹认股权证可立即按名义行使价行使，并向某些投资者发行，这些投资者购买认股权证将导致交易后已发行普通股的所有权超过4.99％或9.99％。此次发行由作为唯一配售代理的A.G.P./Alliance Global Partners尽最大努力进行。作为与Sorrento Therapeutics, Inc.和Scilex Pharmicals Inc.达成的和解协议的一部分，该公司计划将净收益用于营运资金和一般公司用途，并可能支付2024年7月1日到期的250万美元中的一部分。该发行预计将在开始之日后的两个工作日内结束。
处于临床前阶段的制药公司Virpax Pharmicals, Inc.（Virpax）宣布发行多达2,008,032股普通股，以及购买等量股票的A-1和A-2系列普通认股权证。此外，此次发行还包括多达2,008,032份用于购买普通股的预先注资认股权证。预筹认股权证可立即按名义行使价行使，并向某些投资者发行，这些投资者购买认股权证将导致交易后已发行普通股的所有权超过4.99％或9.99％。此次发行由作为唯一配售代理的A.G.P./Alliance Global Partners尽最大努力进行。作为与Sorrento Therapeutics, Inc.和Scilex Pharmicals Inc.达成的和解协议的一部分，该公司计划将净收益用于营运资金和一般公司用途，并可能支付2024年7月1日到期的250万美元中的一部分。该发行预计将在开始之日后的两个工作日内结束。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

独立文件4  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    热议
    美股
    股票代码最新价涨跌幅

    暂无数据

    资讯热榜
    更新时间